Figure 1



Final Survival Per Group
Percentage of Survival (%)
100
90
80
70
60
50
40
30
20
10
0
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Group 8
Group 9
Group 10

Figure 2

MW
E1
E3
VLP
BSA
OVA
TT
MW
150
100
75
50
25
Western immunoblot mAb CAN9G1

Figure 3A and 3B





Figure 4


CAN9G1 C-ELISA (1:800 Dilution)
13F6
PBS Control
GP Control
Absorbance (OD405) at 1 hour
1.2
1.0
0.8
0.6
0.4
0.2
0.0
10
1
0.1
0.01
Concentration (ug/ml)